若生智能
Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Mylan研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Abevmy, bevacizumab, Biocon, Krabeva
公司Mylan
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Mylan

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedTaiwan journal of ophthalmology2026-08-04

Retinopathy of prematurity epidemiology and treatment trend in a tertiary medical center in Taiwan: From 2016 to 2023.

Tseng Yi-Hsuan YH, Wu Pei-Liang PL, Kang Eugene Yu-Chuan EY, Chen Kuan-Jen KJ et al.

To investigate the recent 8-year epidemiology of retinopathy of prematurity (ROP) and treatment modalities in Taiwan. A retrospective study was conducted from 2016 to 2023, using data from Chang Gung Memorial Hospital, Linkou, Taiwan, and enrolling 2078 premature babies who were screened for ROP. The incidence of ROP, type 1 ROP, and initial treatment were analyzed. ROP developed in 671 of the 2078 infants (29.7%), and type 1 ROP was present in 195 infants (9.4%). A declining trend was observed in the number of ROP screenings among premature infants (P = 0.02). The proportion of type 1 ROP decreased significantly from 12.13% in 2016 to 5.0% in 2023 (P < 0.01). Antivascular endothelial growth factor (VEGF) was chosen in 97% and 93.2% of the initial and overall treatments, respectively, with laser mainly used as a secondary treatment. Bevacizumab was the most frequently selected option among the three available anti-VEGF drugs. The incidence of ROP between 2016 and 2023 showed no significant change. The proportion of type 1 ROP decreased during this period. Anti-VEGF was chosen as the initial treatment, and bevacizumab was the most frequently used agent.

PMID 42549255
阅读全文 →
PubMedBeyoglu eye journal2026-08-04

Efficacy and Safety of Intravitreal Triamcinolone Acetonide Alone or Combined with Intravitreal Bevacizumab in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.

Diracoglu Aynur A, Agin Abdullah A, Cakir Mehmet M, Demirok Ahmet A

To compare the efficacy and safety of intravitreal triamcinolone acetonide (IVTA) monotherapy versus combined intravitreal triamcinolone acetonide and bevacizumab (IVTA+IVB) therapy in the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). In this retrospective study, 66 eyes of 65 patients with BRVO-related macular edema were evaluated. Patients were divided into two groups: IVTA monotherapy (n=37) and IVTA+IVB combination therapy (n=29). Central macular thickness (CMT), best-corrected visual acuity (BCVA), and intraocular pressure (IOP) were measured at baseline, week 1, and months 1, 3, and 6 after injection. Both groups demonstrated significant improvements in BCVA and reductions in CMT compared with baseline (p<0.001), with no statistically significant differences between the groups at any follow-up time point. IOP was significantly elevated in the IVTA group at several time points (p<0.05), while the combination group showed stable IOP levels. New-onset glaucoma developed in 8 patients in the IVTA group and only 1 patient in the combination group. No serious ocular complications occurred in either group. Both treatment regimens provided comparable anatomical and visual improvements; however, combination therapy was associated with a more favorable safety profile. Although the use of IVTA has declined in contemporary clinical practice in favor of intravitreal dexamethasone implants, this study suggests that IVTA alone or in combination may still offer a viable and cost-effective alternative in regions where access to current therapies is limited or in low-resource settings.

PMID 42549240
阅读全文 →
PubMedFrontiers in oncology2026-08-04

Association between HER2 expression, genomic characteristics, and tumor immune microenvironment dynamics in epithelial ovarian cancer.

Salinaro Julia J, De La Cruz Payton P, Perati Shriya S, McAdams Julia J et al.

Despite the rapid clinical approval of the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing epithelial ovarian cancer (EOC), preclinical mechanistic studies are lacking.The goal of this investigation was to determine the genomic and immunogenic characteristics associated with HER2 expressing EOC in order to better understand the mechanism of treatment response and what subset of patients will benefit most from single agent and combinatorial HER2-directed treatment regimens. 130 EOC patients were retrospectively identified from our institution's internal clinical genomic database. Selected genomic characteristics were stratified by gastric HER2 score and distributions were analyzed by Fisher's exact test. A subset of 34 EOC tumors were internally HER2 stained and fluorescent immunohistochemistry analysis of PD-L1, CD4, and CD8 was performed. EOC cell lines were treated with T-DXd and PD-L1 and VEGFA levels were assessed via quantitative PCR. VEGF expression following combinatorial T-DXd and bevacizumab treatment was determined via western blot. Non-significant differences were detected in HRD, CCNE1 amplification, and ARID1A status between HER2 high (n=29) and low (n=101) tumors in an EOC and high grade serous ovarian cancer (HGSOC) sub-cohort (n=98). Although not statistically significant, patients with HER2 high tumors had lower levels of FOLR1 positivity and higher levels of PD-L1 positivity in both EOC and HGSOC cohorts. Intratumoral PD-L1 expression and CD4+ T cell levels were significantly higher (p<0.05) in HER2 high tumors. Finally, T-DXd substantially downregulated PD-L1 and VEGFA expression, and bevacizumab and T-DXd synergistically reduced VEGF expression. HER2 high EOC tumors are more likely to be FOLR1 negative and PD-L1 positive, and treatment with T-DXd downregulates PDL-1 and VEGFA expression. These findings support further examination to determine if immunotherapy and anti-angiogenic treatments synergize with T-DXd in EOC.

PMID 42548619
阅读全文 →
PubMedLiver cancer2026-08-04

Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma.

Lee Jinho J, Lee Hye Won HW, Park Mi Ri MR, Shin Saeam S et al.

While immunotherapy has emerged as a promising treatment option, no reliable predictive biomarker has been established for immunotherapy in hepatocellular carcinoma (HCC). In this study, we used genetic analyses to verify the prognostic significance of tumor mutation burden (TMB) in HCC and to search for other cancer characteristics related to prognosis. Patients with HCC who received a combined therapy of atezolizumab and bevacizumab were prospectively enrolled between July 2020 and April 2023. Circulating tumor DNA analysis was performed using next-generation sequencing before immunotherapy (baseline) and 3 weeks after initiation of immunotherapy (follow-up), from which we retrieved non-synonymous baseline, follow-up, vanished (detected only at baseline), and acquired (detected only at follow-up) variants. Gene sets related to cancer hallmarks and representative oncogenic pathways were curated. Forty-two patients were enrolled in this study. Higher TMB was not correlated with better prognosis. Instead, it showed an inverse relationship, with higher baseline TMB significantly associated with shorter progression-free survival (PFS) (median 2.73 vs. 9.17 months, p = 0.04). Among other cancer characteristics, acquired variants in the Wnt/β-catenin (PFS: p = 1.14 × 10-4; overall survival [OS]: p = 0.004) and ATP-dependent chromatin remodeling (PFS: p = 0.002; OS: p = 0.006) pathways were significantly correlated with worse prognosis. In HCC, TMB is not a reliable predictive biomarker for immunotherapy. Instead, the emergence of acquired genetic variants in the Wnt/β-catenin and chromatin remodeling pathways act as a key driver of resistance.

PMID 42549450
阅读全文 →
PubMedRadiology2026-08-04

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

Yoo Jae-Sung JS, Tak Kwon Yong KY, Cho Hee Sun HS, Han Ji Won JW et al.

Background With the advent of immune checkpoint inhibitor-based combination therapy, treatment sequencing for advanced hepatocellular carcinoma (HCC) has become increasingly complex. The Barcelona Clinic Liver Cancer (BCLC) 2026 recommendations emphasize individualized decision-making. Purpose To compare clinical outcomes of hepatic arterial infusion chemotherapy (HAIC) and tyrosine kinase inhibitors (TKIs) in patients with advanced HCC after atezolizumab-bevacizumab (AB) failure, within the BCLC 2026 treatment paradigm. Materials and Methods This multicenter retrospective study included patients who received AB and subsequently received either HAIC or a TKI between March 2022 and August 2025. HAIC used a cisplatin-fluorouracil regimen, and TKIs were given at standard doses. Tumor response and progression-free survival (PFS) were assessed using contrast-enhanced multiphase CT or liver MRI according to routine clinical practice. Imaging was reviewed by radiologists blinded to treatment allocation. Inverse probability of treatment weighting (IPTW) was applied for age, sex, Eastern Cooperative Oncology Group performance status, Child-Pugh class, portal vein tumor thrombosis, and tumor burden based on the up-to-seven criteria. Results This study included 90 patients (mean age, 62 years ± 10.9 [SD]; 73 men; HAIC group, n = 51; TKI group, n = 39). Baseline tumor burden was higher in the HAIC group than in the TKI group (percentage of patients with tumors beyond the up-to-seven criteria: 88% [45 of 51] vs 64% [25 of 39]; P = .01). In unweighted analyses, median overall survival (OS) was similar between the HAIC and TKI groups (10.4 vs 6.4 months; P = .62), whereas PFS favored HAIC over TKIs (median, 5.3 vs 3.6 months; P = .008). Objective response rate and disease control rate were higher with HAIC than with TKIs (objective response rate: 35% [18 of 51] vs 5% [two of 39], P = .002; disease control rate: 67% [34 of 51] vs 26% [10 of 39], P < .001). After IPTW, HAIC remained associated with longer PFS than TKIs (median, 7.1 vs 3.4 months; P < .001), and OS remained similar between groups (median, 10.5 vs 6.3 months; P = .32). Conclusion In patients with advanced HCC, after AB failure, second-line HAIC yielded higher response rates and longer PFS than TKIs. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Deyirmendjian and Tang in this issue.

PMID 42550027
阅读全文 →
PubMedJournal of clinical apheresis2026-08-03

Therapeutic Plasma Exchange for Removal of Bevacizumab: A Case Series.

Gopu Sooraj Srirangadhamu SS, Patell Rushad R, Uhlmann Erik J EJ, Vega Rafael A RA et al.

Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor A. Its long half-life and low volume of distribution allow circulating drug to persist in the body for weeks, which becomes clinically relevant when urgent or emergent surgery is needed. Because bevacizumab is largely intravascular, therapeutic plasma exchange (TPE) is attractive, though published experience is limited. We describe four adults who underwent TPE to facilitate surgery or postoperative wound healing after bevacizumab exposure: two with glioblastoma multiforme (GBM) before craniotomy, one with GBM after bowel resection with primary anastomosis, and one with metastatic rectal adenocarcinoma before craniotomy for a hemorrhagic brain mass. Patients received one to three sessions with albumin replacement, with fresh frozen plasma added in one case. No postoperative hemorrhage or delayed wound healing occurred. These cases support a practical role for TPE when residual bevacizumab exposure remains relevant and awaiting spontaneous clearance is not feasible.

PMID 42543482
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab